Paclitaxel-Eluting or Sirolimus-Eluting Stents to Prevent Restenosis in Diabetic Patients
Top Cited Papers
Open Access
- 18 August 2005
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 353 (7), 663-670
- https://doi.org/10.1056/nejmoa044372
Abstract
Drug-eluting stents are highly effective in reducing the rate of in-stent restenosis. It is not known whether there are differences in the effectiveness of currently approved drug-eluting stents in the high-risk subgroup of patients with diabetes mellitus.Keywords
This publication has 30 references indexed in Scilit:
- Increased Incidence of Coronary Atherosclerosis in Type 2 Diabetes Mellitus: Mechanisms and ManagementAnnals of Internal Medicine, 2003
- Diabetes and Vascular DiseaseCirculation, 2003
- New Frontiers in CardiologyCirculation, 2003
- Gap Between Clinical Trials and Clinical PracticeCirculation, 2003
- Coronary atherosclerosis in diabetes mellitusJournal of the American College of Cardiology, 2002
- A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary RevascularizationNew England Journal of Medicine, 2002
- Cardiovascular Risk Assessment Based on US Cohort StudiesCirculation, 2001
- Importance of Considering Atherosclerosis Progression When Choosing a Coronary Revascularization StrategyCirculation, 1999
- Diabetes mellitus and the clinical and angiographic outcome after coronary stent placementJournal of the American College of Cardiology, 1998
- The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantationJournal of the American College of Cardiology, 1998